BITRF Stock News 0.1250 05/08/2014 06:40:03 Biotron Ltd (BIT

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biotron Ltd (BITRF) 0.1250 $BITRF

Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline

Influenza - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Influenza
M2 - Wed Sep 04, 11:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zj34n7/influenza) has announced the addition of the "Influenza - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Influenza - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Influenza, complete with latest updates, and special features on late-stage and discontinued projects. Influenza - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Influenza. - A review of the Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Influenza pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - 4SC AG - AIMM Therapeutics B.V. - Amarillo Biosciences, Inc. - BioAlliance Pharma SA - Biotron Limited - CEL-SCI Corporation - DiaMedica Inc. - Evolva SA - Functional Genetics, Inc. - Generex Biotechnology Corporation - GlaxoSmithKline plc - Green Cross Corporation - Hawaii Biotech, Inc. - Inovio Biomedical Corporation - Johnson & Johnson - Novartis AG - Novavax, Inc. - Okairos - Panacea Biotec Limited - PaxVax - PepTcell Limited - Quantum Pharmaceuticals - Romark Laboratories, L.C. - Sanofi-Aventis - Trellis Bioscience, Inc. - UMN Pharma Inc. - Vivaldi Biosciences Inc. - Wittycell S.A.S. - XOMA Ltd. - Zosano Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/zj34n7/influenza About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Hepatitis C - Pipeline Review, H2 2013
M2 - Mon Sep 02, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H2 2013" report to their offering. 'Hepatitis C - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Scope - A snapshot of the global therapeutic scenario for Hepatitis C. - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. United Therapeutics Corporation Medgenics Inc. Valeant Pharmaceuticals International GlaxoSmithKline plc Tekmira Pharmaceuticals Corp. Inovio Biomedical Corporation Idenix Pharmaceuticals, Inc. Gilead Sciences, Inc. Biotest AG Merck & Co., Inc. Lentigen Corporation BioLineRx, Ltd. Biotron Limited Novartis AG Isotechnika Pharma Inc. Achillion Pharmaceuticals, Inc. Chugai Pharmaceutical Co. Ltd and many more.... For more information visit http://www.researchandmarkets.com/research/wq...epatitis_c About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Exus Bags $345M Financing for U.S. Energy Growth

Updated Category News Views 41

Something's Stirring in the Renewables Sector You ever feel like the renewable energy world is moving at a breakneck pace? Well, hold onto your hat because Exus Renewables North America just secured a hefty $345 million in financing led by Goldman Sachs Alternatives. It's got "big developments" written all over it, folks. What's the Deal Here? The funds are aimed squarely...

Continue Reading
Wyalusing Valley, Wysox Centers Change Ownership

Updated Category News Views 85

A New Chapter for Pennsylvania's Childcare Gems In the often unpredictable world of childcare services, a shift is happening in Pennsylvania that has John and Robyn Lacy stepping back after two decades of dedicated service. The Wyalusing Valley Children's Center and Wysox Children's Center have found a new home in the hands of a private investor, signifying a significant...

Continue Reading
Southwest Airlines' 191st Quarterly Dividend: A Steady Flight

Updated Category News Views 89

Another Dividend in Southwest’s Long-Running Playbook Well, here we go again, folks. Southwest Airlines (NYSE: LUV) has just waved the flag on their 191st quarterly dividend like clockwork, pegged at $0.18 per share. If you’re into steady-as-she-goes stock scenarios, this is your scene. On December 17, 2026, registered shareholders are gonna see that little bump in...

Continue Reading
JEM Global Brings Smart Outdoor Lights to Walmart

Updated Category News Views 67

Walmart's New Lighting Surprise for the Holidays Throw your boring old holiday lights out the window because JEM Global's just teamed up with Walmart to unleash the Monster Smart 150-Foot RGBIC + Multi-White Permanent Outdoor Lights. Yeah, that means a facelift for your house without breaking the bank—$114.99 to be exact, right off the virtual shelves on Walmart.com and...

Continue Reading
Avionics Market To Hit $84B by 2031: Trend Insights

Updated Category News Views 25

The Flight Path to $84 Billion If there's one thing that'll get the adrenaline pumping for aerospace investors, it's hearing that the avionics market is poised to skyrocket from $61.08 billion in 2026 to a hefty $84.32 billion by 2031. That's not chump change, folks. This anticipated growth at a 6.7% compound annual growth rate signals a bustling market hungry for...

Continue Reading
Keurig Dr Pepper's $2B Debt Reduction: Strategic Move?

Updated Category News Views 34

Beverage Giant Keurig Dr Pepper Selling Big on Stock In the latest twist from the executive suite of Keurig Dr Pepper (NASDAQ: KDP), they've just pushed out a hefty public offering of nearly 58 million shares at $34.50 a pop. We're talking over a two billion dollar game plan here, folks. The deadline for this brew of equity grabs ends November 16, 2026, if all the...

Continue Reading
Bit Digital Shifts Focus: Q3 2026 Sees Strategic Moves

Updated Category News Views 108

Bit Digital's Strategic Shakeup Ah, the digital gold rush is heating up again. Bit Digital, the outfit focused on Ethereum strategies and AI, dropped their financial results for Q3 2026. Picture a company at a strategic crossroads, shedding bitcoin mining baggage to grab hold of fresh opportunities in Ethereum staking and AI infrastructure. Bit Digital's earnings paint a...

Continue Reading
Nuix Names Lori Cornmesser to Head Global Partnerships

Updated Category News Views 75

Nuix Shakes Things Up with New Leadership Nuix, a notable player in the investigative analytics and intelligence software space, just leveled up its game by bringing in Lori Cornmesser as the Global Vice President, Partner Ecosystems. This ain't your average hire. Cornmesser's been around the block—over 25 years, in fact—building and leading partner ecosystems...

Continue Reading
tZERO Gains CFTC Approval, Paves Derivatives Path

Updated Category News Views 33

Breaking into New Territory: tZERO's CFTC Triumph tZERO just scored a touchdown in the financial arena with its newly minted approval from the Commodity Futures Trading Commission. This green light allows them to dive into derivatives trading and clearing, a colossal leap for their Infrastructure-as-a-Service model. You could almost feel the corporate chest-thumping as...

Continue Reading
FF EAI Robotics Aims for Top Spot in K-12 Tech

Updated Category News Views 28

FFR's Shot at Robotics Education Dominance You ever feel like a company is throwing everything but the kitchen sink at an opportunity? That's FF EAI Robotics for you—charging ahead with a hefty laundry list of tech ambitions. They've clocked in about $2.3 million in revenue from their newly acquired robotics wing for the first nine months of 2026, showing a 26% gross...

Continue Reading

Top 5 Most Recently Viewed Articles

Nipocalimab's Unique Design for IgG-Driven Diseases Explored

Updated Category News Views 254

Nipocalimab: A Breakthrough in Treating IgG-Driven Diseases Nipocalimab has emerged as a promising investigational treatment in the realm of IgG-driven alloantibody and autoantibody diseases. Recent results affirm its high-affinity binding characteristics and immunoselective properties. This groundbreaking monoclonal antibody has been shown to significantly reduce IgG...

Continue Reading
FTI Consulting Achieves Robust Earnings Despite Market Challenges

Updated Category News Views 64

FTI Consulting Reports Third Quarter Financial Results FTI Consulting, Inc. (NYSE: FCN) recently announced its financial performance for the third quarter, presenting a noteworthy achievement with earnings of $926 million, marking an increase compared to the previous year. This growth reflects the company's resilience and capacity to adapt amidst fluctuating market...

Continue Reading
FutureFuel Secures Key Approval for Clean Fuel Production

Updated Category News Views 331

FutureFuel Achieves Excise Tax Registration Approval FutureFuel Corp. (NYSE: FF), a leading player in the manufacturing of custom and performance chemicals and biofuels, has recently celebrated a significant success. The company has received its Excise Tax Registration approval from the Internal Revenue Service (IRS). This vital registration marks the first step towards...

Continue Reading
Natural Gas Services Group Increases 2024 EBITDA Guidance

Updated Category News Views 92

Natural Gas Services Group Announces Strong Q3 2024 Results Natural Gas Services Group, Inc. (NYSE: NGS), a prominent provider in the natural gas compression industry, has released its financial results for the third quarter ending September 30, 2024. The company reported significant growth in rental revenue, cash flow from operating activities, and net income, signifying...

Continue Reading
Apple's Leap Forward: C2 Modem Testing Signals 5G Advances

Updated Category News Views 331

Apple Inc. Enters a New Era with C2 Modem Testing Apple Inc. (NASDAQ: AAPL) is taking significant steps in advancing its connectivity technology by reportedly testing its second-generation C2 modem for the upcoming iPhone models. Latest Developments in Modem Technology Recently, a reliable source on X, previously known as Twitter, revealed that Apple is currently in the...

Continue Reading